Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMJGleeson Regulatory News (GLE)

Share Price Information for MJGleeson (GLE)

Share Price is delayed by 15 minutes
Get Live Data
248.50    0.00 (0.00%)
Bid:
241.00
Ask:
245.00
Spread: 4.00 (1.66%)
Market Cap: £144.97m
GLE Live PriceLast checked at - London Stock Exchange

Intraday MJGleeson Share Chart

Trading Update

9 Jul 2020 07:00

RNS Number : 4622S
MJ Gleeson PLC
09 July 2020
 

MJ Gleeson plc (GLE.L)

("Gleeson", "the Company" or "the business")

 

For immediate release

 

 

9 July 2020

 

Notice of Results & Trading Update

 

MJ Gleeson plc (GLE.L), the low-cost housebuilder and strategic land specialist, today provides an update for the year ended 30 June 2020 ("FY2020"). The Company will report its audited full year results on Monday, 14 September 2020.

 

Gleeson Homes

 

Gleeson Homes completed the sale of 1,072 homes during the year, a reduction of 29.9% compared with the previous year's total of 1,529.

 

However, the division has entered the new financial year ("FY2021") in a strong position with a forward order book standing at £145.3m on 1,033 plots (June 2019: £87.6m on 677 plots) and over 1,000 built or part-built homes.

 

Net daily reservations over the last four weeks have risen to more than 80% of pre Covid-19 levels with the majority reserved at prices higher than in January and February 2020.

 

Four new build sites were opened in the last two months of the year bringing the total build sites to 71. Of these sites, 65 are actively selling. The business plans to open more than 25 new sites during FY2021 year and expects to have at least 80 active build sites by the end of the period.

 

Current safe-working protocols are, as expected, having an impact on productivity and build rate. Build activity on sites is currently running at 60% of pre Covid-19 levels and is expected to reach 80% by September 2020.

 

The land pipeline of owned and conditionally purchased plots at 30 June 2020 increased by 1.7% compared to the prior year end, totaling 13,801 plots on 149 sites, of which 6,952 plots have been purchased subject to planning permission.

 

Gleeson Strategic Land

 

During the year Gleeson Strategic Land sold two land interests with the potential to deliver 195 plots for housing development.

 

The division's total portfolio comprises 68 sites, with the potential to deliver 23,314 plots, and 44 acres of commercial land. Of these, planning permission has been granted on 11 sites that have the potential to deliver 3,855 plots (June 2019: 9 sites, 2,929 plots).

 

Prior to Covid-19, the division was seeing strong interest in its consented sites. As the land market reopens this interest is returning, with enquiries from a broad range of housebuilders.

 

Group

 

The Group ended the year with cash balances of £76.8m including £60m drawn on the Company's committed bank facility (30 June 2019: £30.3m net cash). In addition, the Group has a £10m committed overdraft facility which is currently undrawn.

 

The majority of furloughed staff have returned to work, either to site or working from home, and the voluntary management pay cuts introduced in April were reversed on 1 July. No further use of the furlough scheme is anticipated after July.

 

The Board expects the results for FY2020 to be in line with revised market expectations.

 

 

James Thomson, Chief Executive Officer, commented:

 

"The impact of Covid-19 on the FY2020 results is as expected. What is pleasing is that the business has demonstrated its underlying resilience in the face of enormous challenges and we are starting the new financial year in a strong position."

 

"Gleeson Strategic Land's pipeline is strong and housebuilders are returning to the market to acquire much-needed consented land which remains in short supply."

 

"Buying a high-quality affordable Gleeson home remains substantially cheaper than renting - often poor quality - accommodation. With strong demand and reservation levels expected to soon recover to pre Covid-19 levels, our robust pipeline will enable us to open more sites than ever as we continue to deliver on our strategic plan of completing 2,000 homes p.a. in FY2022."

 

"We are confident that, if the current market improvement continues, the Group will see a rapid recovery in FY2021."

 

 

 

Enquiries:

 

 

 

MJ Gleeson plc

James Thomson

Stefan Allanson

 

Chief Executive Officer

Chief Financial Officer

01142 612900

Instinctif

Mark Garraway

Rosie Driscoll

 

07771 860938

07891 564641

N+1 Singer

Shaun Dobson

Rachel Hayes

020 7496 3000

Liberum

Neil Patel

Richard Bootle

 

020 3100 2222

 

 

This announcement is released by MJ Gleeson plc and contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 (MAR), and is disclosed in accordance with the Company's obligations under Article 17 of MAR. Upon the publication of this announcement, this information is considered to be in the public domain.

 

For the purposes of MAR and Article 2 of Commission Implementing Regulation (EU) 2016/1055, this announcement is being made on behalf of the Company by Stefan Allanson, Chief Financial Officer.

 

LEI: 21380064K7N2W7FD6434

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTUPUAUMUPUGBR
Date   Source Headline
25th Mar 20204:35 pmRNSPrice Monitoring Extension
25th Mar 20203:38 pmRNSCovid-19 Update
23rd Mar 20204:40 pmRNSSecond Price Monitoring Extn
23rd Mar 20204:36 pmRNSPrice Monitoring Extension
13th Mar 202012:08 pmRNSSecond Price Monitoring Extn
13th Mar 202012:02 pmRNSPrice Monitoring Extension
9th Mar 20209:49 amRNSDirector/PDMR Shareholding
28th Feb 20207:00 amRNSTotal Voting Rights
13th Feb 202012:02 pmRNSPrice Monitoring Extension
13th Feb 20207:00 amRNSHalf-year Report
10th Feb 20202:32 pmRNSDirector/PDMR Shareholding
31st Jan 20207:00 amRNSTotal Voting Rights
9th Jan 20207:00 amRNSNotice of Results and Trading Update
8th Jan 20206:05 pmRNSDirector/PDMR Shareholding
31st Dec 20197:00 amRNSTotal Voting Rights
20th Dec 20196:09 pmRNSExercise of options, PDMR Dealing and TVR
19th Dec 201912:07 pmRNSSecond Price Monitoring Extn
19th Dec 201912:02 pmRNSPrice Monitoring Extension
18th Dec 201910:15 amRNSDirector/PDMR Shareholding
11th Dec 20195:22 pmRNSPerformance Share Plan award to Directors/PDMRs
9th Dec 201911:31 amRNSDirector/PDMR Shareholding
5th Dec 20193:18 pmRNSResult of AGM
5th Dec 20197:00 amRNSAGM Statement
3rd Dec 20194:07 pmRNSTotal Voting Rights
2nd Dec 20197:01 amRNSIncentive Plan Share Issue
2nd Dec 20197:00 amRNSAppointment of Chief Executive Officer
29th Nov 20197:00 amRNSTotal Voting Rights
12th Nov 20193:40 pmRNSPerformance Share Plan award to Directors/PDMRs
11th Nov 201910:12 amRNSDirector/PDMR Shareholding
4th Nov 20197:00 amRNSNotice of AGM
31st Oct 201912:13 pmRNSRe Committee Appointments
31st Oct 20197:00 amRNSTotal Voting Rights
16th Oct 20193:58 pmRNSHolding(s) in Company
9th Oct 201912:05 pmRNSDirector/PDMR Shareholding
9th Oct 201911:46 amRNSDirector/PDMR Shareholding
8th Oct 20192:09 pmRNSExercise of Options and Total Voting Rights
30th Sep 20197:00 amRNSTotal Voting Rights
24th Sep 20197:00 amRNSAppointment of Non-Executive Directors
24th Sep 20197:00 amRNSDirector/PDMR Shareholding
16th Sep 20197:00 amRNSFinal Results
10th Sep 20195:35 pmRNSDirector/PDMR Shareholding
30th Aug 20197:00 amRNSTotal Voting Rights
14th Aug 20194:35 pmRNSPrice Monitoring Extension
8th Aug 20199:32 amRNSDirector/PDMR Shareholding
7th Aug 20191:40 pmRNSHolding(s) in Company
31st Jul 20197:00 amRNSTotal Voting Rights
11th Jul 201910:55 amRNSDirector/PDMR Shareholding
4th Jul 20197:00 amRNSTrading Update
28th Jun 20197:00 amRNSTotal Voting Rights
10th Jun 20192:16 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.